[go: up one dir, main page]

PT1185649E - Promotor do gene da miostatina e inibicao da sua activacao - Google Patents

Promotor do gene da miostatina e inibicao da sua activacao

Info

Publication number
PT1185649E
PT1185649E PT00941296T PT00941296T PT1185649E PT 1185649 E PT1185649 E PT 1185649E PT 00941296 T PT00941296 T PT 00941296T PT 00941296 T PT00941296 T PT 00941296T PT 1185649 E PT1185649 E PT 1185649E
Authority
PT
Portugal
Prior art keywords
promoter
gene
miostatina
initiation
activation
Prior art date
Application number
PT00941296T
Other languages
English (en)
Inventor
Jinshyun R Wu-Wong
Wang Jiahong
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PT1185649E publication Critical patent/PT1185649E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT00941296T 1999-06-10 2000-06-09 Promotor do gene da miostatina e inibicao da sua activacao PT1185649E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/329,685 US6284882B1 (en) 1999-06-10 1999-06-10 Myostatin gene promoter and inhibition of activation thereof

Publications (1)

Publication Number Publication Date
PT1185649E true PT1185649E (pt) 2005-08-31

Family

ID=23286552

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00941296T PT1185649E (pt) 1999-06-10 2000-06-09 Promotor do gene da miostatina e inibicao da sua activacao

Country Status (10)

Country Link
US (2) US6284882B1 (pt)
EP (1) EP1185649B1 (pt)
JP (1) JP4625602B2 (pt)
AT (1) ATE293691T1 (pt)
CA (1) CA2375820C (pt)
DE (1) DE60019586T2 (pt)
ES (1) ES2240108T3 (pt)
MX (1) MXPA01012665A (pt)
PT (1) PT1185649E (pt)
WO (1) WO2000077206A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878552A1 (en) 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molecular detection of chromosome aberrations
AU3516899A (en) 1998-05-04 1999-11-23 Dako A/S Method and probes for the detection of chromosome aberrations
US6555672B1 (en) * 1998-07-15 2003-04-29 Metamorphix, Inc. Growth differentiation factor promoter and uses therefor
ZA200003786B (en) * 1999-07-30 2002-01-21 Pfizer Prod Inc Myostatin regulatory region, nucleotide sequence determination and methods for its use.
US20040248121A1 (en) * 2001-07-11 2004-12-09 Ravi Kambadur Bioassay for myostatin
EA009056B1 (ru) * 2002-12-20 2007-10-26 Амген, Инк. Связывающие агенты, ингибирующие миостатин
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US8426194B2 (en) * 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
US8460864B2 (en) * 2003-01-21 2013-06-11 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
AU2004312411B8 (en) * 2003-12-31 2011-11-24 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
US20060130157A1 (en) 2004-10-22 2006-06-15 Kevin Wells Ungulates with genetically modified immune systems
WO2006073827A2 (en) 2004-12-30 2006-07-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
EP1855694B1 (en) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense composition for treating muscle atrophy
AU2006226878A1 (en) * 2005-03-23 2006-09-28 Wyeth Detection of GDF-8 modulating agents
CN101137906A (zh) * 2005-03-23 2008-03-05 惠氏公司 对gdf-8调节剂的免疫应答的检测
CA2538208A1 (en) * 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
AU2006321906C1 (en) * 2005-12-06 2014-01-16 Amgen Inc. Uses of myostatin antagonists
US8426374B1 (en) 2006-05-04 2013-04-23 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Method for modifying myostatin expression
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
JP2010540534A (ja) 2007-09-28 2010-12-24 イントレキソン コーポレーション 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用
DK2348827T3 (en) 2008-10-27 2015-07-20 Revivicor Inc IMMUNICIPLY COMPROMATED PETS
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
EP3359668A4 (en) 2015-10-09 2019-06-05 Sarepta Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATING DUCHENNE MUSCLE DYSTROPHY AND ASSOCIATED ILLNESSES THEREOF
WO2025110681A1 (ko) * 2023-11-20 2025-05-30 ㈜라트바이오 신규 프로모터

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
ES2201076T3 (es) * 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
WO1998033887A1 (en) * 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6555672B1 (en) * 1998-07-15 2003-04-29 Metamorphix, Inc. Growth differentiation factor promoter and uses therefor
ZA200003786B (en) 1999-07-30 2002-01-21 Pfizer Prod Inc Myostatin regulatory region, nucleotide sequence determination and methods for its use.

Also Published As

Publication number Publication date
DE60019586D1 (de) 2005-05-25
DE60019586T2 (de) 2006-03-09
US6284882B1 (en) 2001-09-04
MXPA01012665A (es) 2002-07-22
EP1185649A2 (en) 2002-03-13
US6399312B2 (en) 2002-06-04
EP1185649B1 (en) 2005-04-20
ES2240108T3 (es) 2005-10-16
WO2000077206A2 (en) 2000-12-21
ATE293691T1 (de) 2005-05-15
US20010049435A1 (en) 2001-12-06
JP2003528574A (ja) 2003-09-30
JP4625602B2 (ja) 2011-02-02
WO2000077206A3 (en) 2001-12-06
CA2375820A1 (en) 2000-12-21
CA2375820C (en) 2010-07-27

Similar Documents

Publication Publication Date Title
PT1185649E (pt) Promotor do gene da miostatina e inibicao da sua activacao
DE69816280D1 (de) Inhibitoren des impdh-enzyms
AP9901674A0 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders.
ECSP034603A (es) Combinaciones sinergicas que comprenden un inhibidor de renina para enfermedades cardiovasculares
NO995544L (no) Forbindelser og metoder for inhibering av ekspresjonen av VCAM-1
BR9811099A (pt) Inibidores de urocinase
AU3652102A (en) Compounds and their uses
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
DE69840603D1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
IS5985A (is) Frumuviðloðunar-bælandi bólgu-eyðandi og ónæmisbælandi efnasambönd
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
MX9801987A (es) Nuevos derivados de aminoacido, su obtencion y su uso.
EP1244452A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
TW200515917A (en) Methods and compositions for the generation of a protective immune response against SARS-COV
ATE303362T1 (de) Chalcon-derivate mit antiproliferativer aktivität
ATE443044T1 (de) Tace inhibitoren
MXPA02006167A (es) Promocion de la angiogenesis con survivina.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
EA200100930A1 (ru) Способ лечения хозл
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
BG100248A (bg) Инхибитори на скваленсинтетаза
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
WO2004060878A3 (en) Inhibitors of phosphatases
WO2001004354A3 (en) Use of ras inhibitors of inhibiting muscle atrophy